Loading clinical trials...
Loading clinical trials...
Multiple myeloma is the second most common haematological cancer. Recent innovations have made it possible for relapsed/refractory patients to benefit from the innovative immunotherapy of bispecific a...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University Hospital, Toulouse
NCT06827860 · Multiple Myeloma in Relapse
NCT06822972 · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
NCT07032129 · Multiple Myeloma, Multiple Myeloma in Relapse, and more
NCT05853965 · Multiple Myeloma, Multiple Myeloma in Relapse
NCT04776330 · Multiple Myeloma, Neoplasm, Plasma Cell, and more
CHU de Toulouse
Toulouse
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions